Correction to: Journal of Neurology https://doi.org/10.1007/s00415-018-8812-0
In the original article, the co-author’s family name has been published incorrectly. The correct family name should be Constantinescu.
References
Genzyme (2016) Lemtrada [prescribing information]. Genzyme Corporation, Cambridge
Cohen JA, Coles AJ, Arnold DL et al (2012) CARE MS I Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380:1819–1828. https://doi.org/10.1016/S0140-6736(12)61769-3
Coles AJ, Twyman CL, Arnold DL et al (2012) CARE MS II Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829–1839. https://doi.org/10.1016/S0140-6736(12)61768-1
Havrdova E, Arnold DL, Cohen JA et al (2017) Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology 89:1107–1116. https://doi.org/10.1212/WNL.0000000000004313
Coles AJ, Cohen JA, Fox E et al (2017) Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology 89:1117–1126. https://doi.org/10.1212/WNL.0000000000004354
Al-Sawaf O, Fischer K, Herling CD et al (2017) Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. Eur J Haematol 98:254–262. https://doi.org/10.1111/ejh.12825
Osterborg A, Foa R, Bezares RF et al (2009) Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 23:1980–1988. https://doi.org/10.1038/leu.2009.146
Sylvan ES, Lundin J, Ipek M et al (2014) Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients. Ann Hematol 83:1725–1733. https://doi.org/10.1007/s00277-014-2105-1
Morgan RD, O’Callaghan JM, Knight SR et al (2012) Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation 93:1179–1188. https://doi.org/10.1097/TP.0b013e318257ad41
Van der Zwan M, Baan CC, Van Gelder T et al (2018) Review of the clinical pharmacokinetics and pharmacodynamics of alemtuzumab and its use in kidney transplantation. Clin Pharmacokinet 57:191–207. https://doi.org/10.1007/s40262-017-0573-x
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical standards
This study has been approved by the local institutional review board and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Tallantyre, E.C., Whittam, D.H., Jolles, S. et al. Correction to: Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol 265, 1123 (2018). https://doi.org/10.1007/s00415-018-8833-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-018-8833-8